BioMedInvest in CHF106m final close

Swiss life sciences firm BioMed Partners has closed its second fund, BioMedInvest II, with CHF106m (€73m) in commitments.

The new vehicle, which will invest in private early- to mid-stage companies in Germany, Switzerland and neighbouring European countries, is backed by both existing and new investors, including the European Investment Fund.

In addition, the firm has added Karl Deres to the team as a venture partner.

Founded in 2003, BioMedPartners’ successes include the trade sale of ESBATech to Alcon for $589m (€405.9m), and the listing of Evolva on the Swiss International Exchange.